Dr. Bruce Bode Looks Back and Forward at Automated Glucose Control Systems in Hospital Settings at ATTD20 Close Concerns and diaTribe covered Glytec co-founder Dr. Bruce Bode’s presentation ATTD 2020 (Advanced Technologies & Treatments for Diabetes) as he explored the past, present and future of automated glucose control systems in hospital settings Dr. Bruce Bode summarized decades of experience in …
MARCH 3, 2020 Glytec and AdventHealth Highlight the Broad Impact of Electronic Glycemic Management at HIMSS 2020 As One-Third of Patients Experience Increased Hospital Stays, Readmissions and Costs Due to Hypoglycemia and Hyperglycemia, eGMS Improves Outcomes and Quality of Care WALTHAM, MASS. (March 3, 2020) – Glytec, the only provider of insulin management software across the continuum of care, today …
AdventHealth Waterman and Sentara Virginia Beach General Hospital showcased reductions in hypoglycemia and glycemic practice variation utilizing Glytec’s comprehensive systems approach to glucose management.
In partnership with clinical leaders from AdventHealth Waterman and Sentara Virginia Beach General Hospital, Glytec presented two storyboards at the IHI National Forum revealing significant quality and safety improvements for hospitalized patients receiving insulin therapy. On average, this population represents as many as one of every three patients admitted to a general ward and one of every two patients admitted to an intensive care unit. Both hospitals credit their collaboration with Glytec, including utilization of the company’s FDA-cleared decision support platform, eGlycemic Management System® (eGMS®), as well as the company’s highly-tailored quality improvement services.
Results of a nationwide survey indicate most hospitals do not employ best practices in glucose control, which leads to increased safety risks, higher readmission rates and significantly greater costs.
According to a recent survey, more than 75% of U.S. hospitals employ an outdated form of insulin therapy inconsistent with recommendations by the American Diabetes Association, American Association of Clinical Endocrinologists, Society of Hospital Medicine and other authoritative sources.
Glytec, the pioneer of digital therapeutics, has hired an expert team of clinicians to help clients drive and sustain full adoption of best practices in glycemic management.
Hospitals and health systems looking to establish brand dominance, competitive distinction and clinical excellence in diabetes care can turn to a team of experts at Glytec dedicated to helping facilitate full adoption of best practices.
Georgia’s largest health system is heightening the safety and efficacy of insulin therapy across its network of hospitals.
Known nationally for innovative care models, WellStar Health System, in partnership with Glytec, is taking proactive measures to optimize glycemic management for hospitalized patients. The not-for-profit health system is expanding use of Glytec’s patented and FDA-cleared eGlycemic Management System® (eGMS®) beyond its two largest facilities, WellStar Kennestone Hospital and WellStar Atlanta Medical Center, to an additional eight facilities in the Greater Atlanta and surrounding area.
The not-for-profit community medical center is partnering with Glytec to facilitate standardization of best practices in diabetes therapy management.
With as many as half of critical care patients either diagnosed with diabetes or at risk of hyperglycemia while hospitalized, Northeast Georgia Medical Center, in partnership with Glytec, is taking advanced measures to optimize glycemic management and ensure the safety and efficacy of insulin therapy. “Our organization is steadfastly committed to clinical excellence in diabetes care and glycemic management,” says Dr. Suhel Patel, Medical Director and Chair, Inpatient Medicine, Northeast Georgia Physicians Group. “By adopting the Glytec suite of technologies and services, our patients will receive insulin therapy that is personalized to their individual needs and carefully designed to support their recovery and transitions of care.”
Results of a study by Drs. Guillermo Umpierrez and Jordan Messler observed markedly lower rates of hypoglycemia and hyperglycemia among critical care patients managed with Glytec’s eGlycemic Management System® versus usual care.
Delivering the highest quality care in accordance with best practice is a fundamental tenet of diabetes and glycemic management at Grady Hospital of Atlanta, Georgia, which is why in 2016, the academic medical center chose to standardize its approach and elevate both safety and efficacy by implementing Glytec’s eGlycemic Management System® (eGMS®) in its intensive care and step-down units. A retrospective analysis conducted by Drs. Guillermo Umpierrez and Jordan Messler, and presented at the American Diabetes Association 79th Scientific Sessions, observed that outcomes of patients managed with eGMS® were consistently superior to those managed with a standard protocol. Outcomes measured over a two-year period (December 2016 to December 2018) included incidence of hypoglycemia, incidence of hyperglycemia, target glucose attainment, and reduction in admission-to-discharge blood glucose.
New product will be the market’s first and only to enable optimization of ALL diabetes medications, insulin and non-insulin alike.
In spite of greater than 80 medications currently available in the U.S. to treat diabetes, less than half of the estimated 22 million people prescribed one or more are maintaining blood sugar levels within the acceptable range. The consequences not only impact health status and quality of life, they add to the growing economic burden of diabetes estimated in 2017 at $327 billion. With multiple patent allowances for its novel Therapy Advisor® software-as-a-medical-device and active engagement in the FDA 510(k) process, Glytec is poised to improve these clinical and financial outcomes by helping providers more easily and efficaciously select and dose all varieties of diabetes medications. No solution of like kind is currently available, Therapy Advisor® will be the first.
The digital therapeutics pioneer is expanding its intellectual property footprint beyond the U.S., gaining worldwide protections for its proprietary diabetes therapy management solutions.
The rise in diabetes is truly a global phenomenon. The World Health Organization has been vocal about the estimated 422 million people living with diabetes, saying: “the prevalence of diabetes is steadily increasing everywhere” and “diabetes and its complications impact harshly on the finances of individuals and their families, and the economies of nations.” Glytec recognizes that optimizing diabetes medications and making insulin a more effective and accessible option stands to benefit not only those living in the U.S, but people around the world. To that end, the company is growing its intellectually property portfolio on an international scale.